Form 4: CareDx Director Michael Goldberg Receives RSU Grant

Director Michael Goldberg acquired 9,795 restricted stock units in CareDx, Inc. as part of an equity compensation grant.

Summary

• Director Michael Goldberg was granted 9,795 restricted stock units (RSUs) of CareDx, Inc. common stock.
• The transaction occurred on June 12, 2026.
• The RSUs were granted at a price of $0 per share as part of equity compensation.
• Following this transaction, the reporting person's total beneficial ownership is 195,737 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• The grant reflects ongoing commitment from a member of the board of directors.

Negatives

• None identified in this filing.

Risks

• Vesting is subject to the reporting person's continuous service to the company.

Future Outlook

The RSUs vest 100% on the earlier of the one-year anniversary of the grant or the day immediately before the first Annual Meeting occurring after the grant date, contingent upon continuous service.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices designed to incentivize long-term board oversight and alignment with shareholder value in the biotechnology and diagnostics sector.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for publicly traded life sciences companies.
• The vesting schedule aligns with typical one-year cliff vesting structures observed in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of the 9,795 RSUs upon the earlier of the one-year anniversary or the next Annual Meeting.

Key Dates

Keywords

CareDx, CDNA, Form 4, Insider Transaction, Restricted Stock Units, Equity Compensation